Last updated: 2026-09-07 07:36:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Repligen Corp. (RGEN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $167.43, with a market capitalization of $9.46B and a P/E ratio of 227.70. Over the past 52 weeks, its price has ranged from $100.99 to $188.73. This page covers its latest market performance, valuation, price trends and company information.
$9.46B | |
$167.26 | |
$327.32 | |
$1.22 | |
$169.61 | |
696.10K | |
1.13M | |
227.70 | |
$188.73 | |
$100.99 | |
-- | |
-- |
Repligen Corp. (RGEN) last closed at $169.61 as of 2026-09-04 23:31:00, unchanged from the previous close of $169.61.
During the latest regular trading session, RGEN traded between $1.22 and $327.32, with a volume of 696.10K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Repligen Corp. (RGEN) moved from $182.03 to $167.43, representing a decline of 8.02% ($14.60).
The stock traded between $165.00 and $183.09 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 959.62 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 75.7%
RGEN is currently trading at $167.43, placing it 75.7% of the way from its 52-week low of $100.99 to its 52-week high of $188.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 2000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Repligen Corp. (RGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.